Comparison
Exenatide vs. Ipamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
141758-74-9
170851-70-4
Molecular weight
4186.6 g/mol
711.86 g/mol
Half-life
2.4 h
2 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSAib-His-D-2-Nal-D-Phe-Lys-NH2Mechanism of action
Exenatide
Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
4
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
2
1